Vortioxetine as adjunctive treatment of negative symptoms in patients with schizophrenia: a double blind and placebo controlled trial
Latest Information Update: 30 Jun 2021
At a glance
- Drugs Vortioxetine (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- 22 Dec 2017 According to IRCT201710241556N100, Expected recruitment end date will be 8 Nov 2019 (planned).
- 20 Dec 2017 New trial record